Iniskedyul ni Atara ang Type A FDA meeting para sa tab-cel CRL

Naka-iskedyul ang FDA ng Type A meeting kasama ang Pierre Fabre para talakayin ang CRL noong Enero 9, 2026 para sa tab-cel BLA. Ang meeting ay tutugunan ang mga punto ng CRL at tuklasin ang muling pagsusumite gamit ang bagong nakolektang datos ng efficacy. Inaasahan ni Atara na magbigay ng regulatory update sa Q2 2026.

Mahahalagang fact

Na-file: Mar 12, 2026, 12:10 PM
Kaganapan: Naiskedyul ang advisory committee
Direksyon: Neutral
Kumpanya: ATRAAtara Biotherapeutics, Inc
Asset: tabelecleucel
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

8-K 0001604464 false 0001604464 2026-03-12 2026-03-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Atara Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36548 46-0920988 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1280 Rancho Conejo Blvd Thousand Oaks , California 91320 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (805) 623-4211 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the

SEC 8-K